Key facts
- This page summarizes Jennifer Cote's Form 4 filing for HARVARD BIOSCIENCE INC (HBIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Mar 2025, 16:50.
Jennifer Cote - 19 Mar 2025 Form 4 Insider Report for HARVARD BIOSCIENCE INC (HBIO)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- HBIO
- Reported as of
- 19 Mar 2025
- Net transaction value
- -$3,916
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2025, 16:50:40 UTC
- Prior SEC filing
- 31 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Fry, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jennifer Cote filed Form 4 for HARVARD BIOSCIENCE INC (HBIO) on 21 Mar 2025.
Change
- Previous filing in this sequence was filed on 31 Dec 2024.
- Current net transaction value: -$3,916.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HBIO
transaction
Common Stock
Tax liability
- Transaction value
- $3,916
- Shares
- -5,687
- Change %
- -3.5%
- Price
- $0.6886
- Shares after
- 159,019
- Date
- 19 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested in part on March 19, 2025.
Footnote F2
Includes (a) 8,964 RSUs that will vest on December 29, 2025, (b) 23,867 RSUs that will vest in two equal installments on March 19, 2026 and 2027, (c) 35,800 RSUs with performance based vesting conditions tied to achievements by the Company of certain performance criteria, (d) 25,862 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 64,526 shares of common stock (which includes 4,496 shares acquired on December 31, 2024 under the Issuer's Employee Stock Purchase Plan) beneficially owned by the Reporting Person.